WO2025006149A3 - Méthodes de réduction de l'antigène de surface du virus de l'hépatite b (hbsag) et les médicaments de l'hépatite b utilisés dans les méthodes correspondantes - Google Patents

Méthodes de réduction de l'antigène de surface du virus de l'hépatite b (hbsag) et les médicaments de l'hépatite b utilisés dans les méthodes correspondantes Download PDF

Info

Publication number
WO2025006149A3
WO2025006149A3 PCT/US2024/032725 US2024032725W WO2025006149A3 WO 2025006149 A3 WO2025006149 A3 WO 2025006149A3 US 2024032725 W US2024032725 W US 2024032725W WO 2025006149 A3 WO2025006149 A3 WO 2025006149A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hbsag
surface antigen
drugs used
virus surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/032725
Other languages
English (en)
Other versions
WO2025006149A2 (fr
Inventor
Yong-yuan ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hbvtech LLC
Original Assignee
Hbvtech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hbvtech LLC filed Critical Hbvtech LLC
Priority to CN202480042646.8A priority Critical patent/CN121548432A/zh
Priority to AU2024307581A priority patent/AU2024307581A1/en
Priority to EP24832667.0A priority patent/EP4735477A2/fr
Publication of WO2025006149A2 publication Critical patent/WO2025006149A2/fr
Publication of WO2025006149A3 publication Critical patent/WO2025006149A3/fr
Priority to MX2025015430A priority patent/MX2025015430A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode de traitement d'une infection d'hépatite B chronique chez l'homme, la méthode comprenant l'administration à un sujet dont l'état le nécessite, d'une quantité efficace de l'un et/ou l'autre d'un anticorps anti-HBs exogène et d'un vecteur de production d'anticorps anti-HBs pour réduire l'antigène de surface du virus de l'hépatite B (HBsAg) cellulaire et sanguin, en assurant un taux élevé d'anticorps anti-HBs à effet prolongé chez le sujet.
PCT/US2024/032725 2023-06-27 2024-06-06 Méthodes de réduction de l'antigène de surface du virus de l'hépatite b (hbsag) et les médicaments de l'hépatite b utilisés dans les méthodes correspondantes Ceased WO2025006149A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202480042646.8A CN121548432A (zh) 2023-06-27 2024-06-06 用于减少乙型肝炎病毒表面抗原（HBsAg）的方法以及在其方法中使用的乙型肝炎药物
AU2024307581A AU2024307581A1 (en) 2023-06-27 2024-06-06 Methods for reducing hepatitis b virus surface antigen (hbsag) and drugs used in the methods thereof
EP24832667.0A EP4735477A2 (fr) 2023-06-27 2024-06-06 Méthodes de réduction de l'antigène de surface du virus de l'hépatite b (hbsag) et les médicaments de l'hépatite b utilisés dans les méthodes correspondantes
MX2025015430A MX2025015430A (es) 2023-06-27 2025-12-17 Metodos para reducir antigeno de superficie del virus de la hepatitis b (hbsag) y los farmacos de hepatitis usados en los metodos de los mismos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506582P 2023-06-27 2023-06-27
US63/506,582 2023-06-27

Publications (2)

Publication Number Publication Date
WO2025006149A2 WO2025006149A2 (fr) 2025-01-02
WO2025006149A3 true WO2025006149A3 (fr) 2025-02-13

Family

ID=93940110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032725 Ceased WO2025006149A2 (fr) 2023-06-27 2024-06-06 Méthodes de réduction de l'antigène de surface du virus de l'hépatite b (hbsag) et les médicaments de l'hépatite b utilisés dans les méthodes correspondantes

Country Status (5)

Country Link
EP (1) EP4735477A2 (fr)
CN (1) CN121548432A (fr)
AU (1) AU2024307581A1 (fr)
MX (1) MX2025015430A (fr)
WO (1) WO2025006149A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136378B2 (en) * 2015-11-30 2021-10-05 HBVtech LLC Methods of curing HBV infection and providing complete protection against HBV infection
WO2022029209A1 (fr) * 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Traitement par oligonucléotides des patients atteints d'hépatite b
WO2023122555A2 (fr) * 2021-12-21 2023-06-29 Hbvtech, Llc. Méthodes d'élimination du cccdna et du rcdna du virus de l'hépatite b et médicaments contre l'hépatite b utilisés dans les méthodes associées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136378B2 (en) * 2015-11-30 2021-10-05 HBVtech LLC Methods of curing HBV infection and providing complete protection against HBV infection
WO2022029209A1 (fr) * 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Traitement par oligonucléotides des patients atteints d'hépatite b
WO2023122555A2 (fr) * 2021-12-21 2023-06-29 Hbvtech, Llc. Méthodes d'élimination du cccdna et du rcdna du virus de l'hépatite b et médicaments contre l'hépatite b utilisés dans les méthodes associées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VANWOLLEGHEM THOMAS, ADOMATI TOM, VAN HEES STIJN, JANSSEN HARRY L.A.: "Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV", JHEP REPORTS, vol. 4, no. 2, 1 February 2022 (2022-02-01), pages 100398, XP093280475, ISSN: 2589-5559, DOI: 10.1016/j.jhepr.2021.100398 *
ZHANG Y-Y, NORDENFELT E, HANSSON B G: "INCREASING HETEROGENEITY OF THE 'A' DETERMINANT OF HBSAG FOUND IN THE PRESUMED LATE PHASE OF CHRONIC HEPATITIS B VIRUS INFECTION", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES., SCANDINAVIAN UNIVERSITY PRESS, OSLO., NO, vol. 28, no. 01, 1 January 1996 (1996-01-01), NO , pages 09 - 15, XP009037983, ISSN: 0036-5548 *

Also Published As

Publication number Publication date
MX2025015430A (es) 2026-03-02
AU2024307581A1 (en) 2026-01-08
EP4735477A2 (fr) 2026-05-06
WO2025006149A2 (fr) 2025-01-02
CN121548432A (zh) 2026-02-17

Similar Documents

Publication Publication Date Title
CY1123667T1 (el) Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου
Li et al. Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant
JP2024170522A5 (fr)
RU2319505C2 (ru) Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения
MX2025015430A (es) Metodos para reducir antigeno de superficie del virus de la hepatitis b (hbsag) y los farmacos de hepatitis usados en los metodos de los mismos
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
JP2022513001A5 (fr)
WO2003078595B1 (fr) Compositions et procedes permettant d'initier ou d'ameliorer les reponses des cellules t limitees par le complexe majeur d'histocompatibilite de classe i ou ii et un anticorps au moyen de motifs d'arn non codants immunomodulateurs
CN120939215A (zh) 一种治疗或预防乙肝病毒感染的疫苗
WO2023122555A3 (fr) Méthodes d'élimination du cccdna et du rcdna du virus de l'hépatite b et médicaments contre l'hépatite b utilisés dans les méthodes associées
CN105903034A (zh) 一种香菇多糖修饰的碳纳米管及其制备方法与应用
JP2005505582A (ja) ヒトモノクロナール抗体によるｂ型肝炎ウイルス感染の治療
WO2020254878A8 (fr) Composition thérapeutique améliorée contenant l'antigène de l'hépatite b présentant des protéines s, pré-s1 et pré-2, du phosphate d'aluminium et l'interféron alpha et utilisation du traitement de l'hépatite b
CA2112508A1 (fr) Immunogenicite d'un vaccin par inclusion d'une cytokine a l'interieur d'un complexe immuno-stimulant qui contient un antigene
WO2003032917A3 (fr) Vaccin contre l'ankylostome
Yvonnet et al. Immunogenic effect of hepatitis B vaccine in children: Comparison of two‐and three‐dose protocols
EP0339668A3 (fr) Antigène à base du virus de l'hépatite A
Yuen et al. Preliminary safety and efficacy of the combination therapy of BRII-835 and BRII-179 treating chronic HBV infection
WO2024263918A3 (fr) Évaluation et traitement de l'hépatite b chronique
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
CN121405821B (zh) 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用
WO2021203013A3 (fr) Méthodes de traitement d'une lésion pulmonaire à médiation immunitaire
MX2022004399A (es) Metodos para tratar infecciones viricas por hepatitis delta.
Uchaikin et al. Use of recombinant alpha-2b-interferon in combination with antioxidants in the form of rectal suppositories (viferon) in children with chronic hepatitides B and C
Ma et al. Maintenance Mechanism of Chronic HBV Infection and the Strategy for Functional Cure

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024307581

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/015430

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025576606

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025029097

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024307581

Country of ref document: AU

Date of ref document: 20240606

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24832667

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020267002226

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024832667

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202508275S

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508275S

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024832667

Country of ref document: EP

Effective date: 20260127

ENP Entry into the national phase

Ref document number: 2024832667

Country of ref document: EP

Effective date: 20260127

WWP Wipo information: published in national office

Ref document number: MX/A/2025/015430

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2024832667

Country of ref document: EP